Apollo Hospitals Enterprise Limited announced the outcome of its Board Meeting held on February 10, 2026. The Board declared an interim dividend of Rs. 10/- per share (200% of face value) for FY2025-26, with a record date set for February 16, 2026. Concurrently, the Board approved the unaudited standalone and consolidated financial results for the three and nine months ended December 31, 2025 (Q3FY26). The results showcased strong YoY growth across key metrics.
Apollo Hospitals Enterprise Limited held its Board Meeting on February 10, 2026, transacting key business items including the approval of quarterly financial results and the declaration of an interim dividend.
Interim Dividend Declaration
The Board of Directors declared an interim dividend of Rs. 10/- per share, which represents 200% of the face value of Rs. 5/- per share for the financial year ending March 31, 2026.
- Record Date: February 16, 2026.
- Payment Date: On or before February 27, 2026.
Unaudited Financial Results (Q3FY26)
Standalone Performance Highlights (For the three months ended December 31, 2025)
The unaudited standalone results, subject to Limited Review, showed robust performance:
- Total Income: Rs. 24,717 Million, up from Rs. 21,627 Million in the corresponding period last year.
- Profit After Tax (PAT): Rs. 3,811 Million, compared to Rs. 3,391 Million in Q3FY25.
- Earnings Per Share (EPS) Basic & Diluted: *Rs. 26.67 for the quarter (not annualized).
Consolidated Performance Highlights (Q3FY26 vs Q3FY25)
The press release highlights strong consolidated growth for the quarter:
- Consolidated Revenue: Grew 17% YoY to Rs. 6,477 Crore.
- Consolidated EBITDA: Grew 27% YoY to Rs. 965 Crore.
- Consolidated PAT: Grew 35% YoY to Rs. 502 Crore.
- Diluted EPS: Rs. 34.94 per share (not annualized).
- GMV of Apollo 24/7: Stood at Rs. 525 Crore.
Consolidated Performance Highlights (Year-to-Date Dec FY26 vs YTD Dec FY25)
For the nine months ended December 31, 2025:
- Consolidated Revenue: Grew 15% YoY to Rs. 18,623 Crore.
- Consolidated EBITDA: Grew 22% YoY to Rs. 2,758 Crore.
- Consolidated PAT: Grew 34% YoY to Rs. 1,412 Crore.
Segment Performance Insights (Q3FY26)
Healthcare Services (Hospitals)
This division demonstrated steady clinical performance:
- Revenue Growth: Increased 14% YoY to Rs. 3,183 crore.
- EBITDA Growth: Increased 18% YoY to Rs. 790 crore, with margins at 24.8%.
- The network operated 8,072 beds with an overall occupancy of 67%.
Apollo HealthCo (Digital & Pharmacy)
The digital and omni-channel segment continued its strong growth trajectory:
- Revenue Growth: Grew 20% YoY to Rs. 2,827 crore.
- EBITDA: Reached Rs. 128 crore, a significant increase from Rs. 57 crore in Q3FY25.
- Store Expansion: 185 net new stores opened, taking the total to 7,113 stores.
Apollo Health and Lifestyle Limited (Diagnostics & Retail)
This unit saw strong double-digit revenue expansion:
- Revenue Growth: Grew 20% YoY to Rs. 467 crore.
- EBITDA Growth: Increased 39% YoY to Rs. 48 crore.
Clinical and Operational Milestones
The Chairman, Dr. Prathap C Reddy, highlighted several significant clinical achievements:
- Transformational Paediatric Breakthrough: Successful treatment of a 13-month-old with Spinal Muscular Atrophy (Type 1) using gene therapy.
- New Launches: Introduction of a dedicated Centre of Excellence for Parkinson’s and DBS care in Chennai, and the launch of a 250-bed facility in Pune.
- The transplant program reached a cumulative milestone of over 21,000 kidney transplants and 5,000 liver transplants.
Corporate Social Responsibility
The Apollo Foundation reached 276,369 beneficiaries during the quarter through its flagship programs, Billion Hearts Beating (BHB) and Total Health (TH).
Source: BSE
